Clinical trials: Nasal Polyps
Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
The primary objective of the study is to evaluate the safety and effectiveness of OCEAN as an adjunct aid in wound healing after nasal/sinus surgery and to demonstrate that OCEAN is non-inferior compared to a steroid-eluting…
- Trial name
- ENHANCE II (NCT07286201)
- Testing
- OCEAN, Steroid-eluting sinus stent
- Where
- 9 sites in United States
- Volunteers
- 110 people
- Sponsor
- Polyganics BV
Nasal Polyposis
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video.
- Trial name
- NCT03591068
- Testing
- Fluticasone Propionate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis Without Nasal Polyps
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
ACT18421 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups.
- Trial name
- NCT06691113
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 66 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis Without Nasal Polyps
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with…
- Trial name
- Re-Open 3 (NCT06850805)
- Testing
- OPN-375
- Where
- 24 sites in United States
- Volunteers
- 84 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), whose…
- Trial name
- PETRICHOR (NCT07633158)
- Where
- 19 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Nasal Polyps
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT07701967
- Testing
- Depemokimab
- Where
- 10 sites in Japan
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A study to evaluate the safety and efficacy of multiple doses of etokimab in adults with chronic rhinosinusitis with nasal polyps.
- Trial name
- NCT03614923
- Testing
- Etokimab, Mometasone Furoate Nasal Spray
- Where
- 28 sites in United States
- Volunteers
- 105 people
- Sponsor
- AnaptysBio, Inc.
Chronic Rhinosinusitis With Nasal Polyps
A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
Primary Objective: To describe the clinical characteristics of participants with chronic rhinosinusitis with nasal polyps (CRSwNP) in terms of disease severity, Type 2 inflammation-related comorbidities (such as asthma and…
- Trial name
- NCT05649813
- Where
- Kuwait
- Volunteers
- 148 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and…
- Trial name
- NCT07807826
- Testing
- CM512
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.
Bilateral Nasal Polyposis
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a…
- Trial name
- NCT03747458
- Testing
- OPN-375
- Where
- 31 sites in United States, Argentina
- Volunteers
- 40 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis With Nasal Polyps
Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps
This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
- Trial name
- NCT05626257
- Testing
- Xolair
- Where
- 16 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the…
- Trial name
- NCT07313917
- Testing
- LP-003 Injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Longbio Pharma
Nasal Polyps, Chronic Rhinosinusitis
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to…
- Trial name
- POLYP 1 (NCT03280550)
- Testing
- Omalizumab
- Where
- 37 sites in United States, Canada and 8 more
- Volunteers
- 138 people
- Sponsor
- Hoffmann-La Roche
Chronic Rhinosinusitis Without Nasal Polyps
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
- Trial name
- BiRCh (NCT06013241)
- Testing
- Brensocatib, Mometasone furoate nasal spray (MFNS)
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 288 people
- Sponsor
- Insmed Incorporated
Polyp of Ethmoidal Sinus, Surgery
RESPIMER® Netiflow® vs. Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy (Nasal Polyposis)
The main objective of this study is to compare the effects of RESPIMER® NetiFlow® solution and device versus saline solution (0.9% NaCl), the standard treatment, used with RESPIMER® NetiFlow® device, both used postoperative care…
- Trial name
- NETIFLOW (NCT02559284)
- Testing
- A postoperative care after ethmoid sinus surgery
- Where
- 8 sites in France
- Volunteers
- 189 people
- Sponsor
- Laboratoire de la Mer
Chronic Rhinosinusitis With Nasal Polyps
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical…
- Trial name
- ENSEMBLE (NCT06914908)
- Testing
- Lunsekimig, Mometasone furoate nasal spray (MFNS)
- Where
- 24 sites in United States, Argentina and 4 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab CRSwNP Real World Study (CREW Study)
The CREW Study is a non-interventional prospective, observational study in patients with CRSwNP that will evaluate patient-reported outcomes and describe the proportion of participants achieving treatment goals.)
- Trial name
- CREW (NCT07790198)
- Testing
- Tezepelumab
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyposis
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal…
- Trial name
- OPALE (NCT06393946)
- Testing
- Dupilumab
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Sanofi
Nasal Polyps
A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.
- Trial name
- NCT01386125
- Testing
- Mometasone Furoate Nasal Spray (MFNS)
- Volunteers
- 748 people
- Sponsor
- Organon and Co
Chronic Sinusitis Without Nasal Polyps
A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
The purpose of this clinical trial is to assess the efficacy and safety of HTMC0658 tablets in treating subjects with chronic rhinosinusitis without nasal polyps (CRSsNP).
- Trial name
- NCT07174115
- Testing
- HTMC0658
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.